| [1] |
Siegel RL, Miller KD, Jemal A.
Cancer statistics, 2020[J]. CA Cancer J ClinCA Cancer J Clin, 2020, 70(1): 7-30.
doi: 10.3322/caac.21590 |
| [2] |
Bray F, Ferlay J, Soerjomataram I, et al.
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J ClinCA Cancer J Clin, 2018, 68(6): 394-424.
doi: 10.3322/caac.21492 |
| [3] |
Lau SC, Cheung WY. Evolving treatment landscape for early and advanced pancreatic cancer[J/OL]. World J Gastrointest Oncol, 2017, 9(7): 281−292[2021-03-27]. https://www.wjgnet.com/1948-5204/full/v9/i7/281.htm. DOI: 10.4251/wjgo.v9.i7.281. |
| [4] |
Lee JW, O JH, Choi M, et al. Impact of 18F-fluorodeoxyglucose PET/CT and PET/MRI on initial staging and changes in management of pancreatic ductal adenocarcinoma: a systemic review and meta-analysis[J/OL]. Diagnostics (Basel), 2020, 10(11): 952[2021-03-27]. https://www.mdpi.com/2075-4418/10/11/952. DOI: 10.3390/diagnostics10110952. |
| [5] |
Quick HH.
Integrated PET/MR[J]. J Magn Reson ImagingJ Magn Reson Imaging, 2014, 39(2): 243-258.
doi: 10.1002/jmri.24523 |
| [6] |
Broski SM, Goenka AH, Kemp BJ, et al.
Clinical PET/MRI: 2018 update[J]. AJR Am J RoentgenolAJR Am J Roentgenol, 2018, 211(2): 295-313.
doi: 10.2214/ajr.18.20001 |
| [7] |
Ward RD, Amorim B, Li WE, et al.
Abdominal and pelvic 18F-FDG PET/MR: a review of current and emerging oncologic applications[J]. Abdom Radiol (NY)Abdom Radiol (NY), 2021, 46(3): 1236-1248.
doi: 10.1007/s00261-020-02766-2 |
| [8] |
曾天翼, 宋少莉, 吕力琅.
一体化PET/MR技术的发展及临床应用[J]. 肿瘤影像学肿瘤影像学, 2019, 28(4): 276-282.
doi: 10.19732/j.cnki.2096-6210.2019.04.013 Zeng TY, Song SL, Lyu LL. Technical progress and clinical application of integrated PET/MR[J]. OncoradiologyOncoradiology, 2019, 28(4): 276-282. doi: 10.19732/j.cnki.2096-6210.2019.04.013 |
| [9] |
Torigian DA, Zaidi H, Kwee TC, et al.
PET/MR imaging: technical aspects and potential clinical applications[J]. RadiologyRadiology, 2013, 267(1): 26-44.
doi: 10.1148/radiol.13121038 |
| [10] |
Tatsumi M, Isohashi K, Onishi H, et al.
18F-FDG PET/MRI fusion in characterizing pancreatic tumors: comparison to PET/CT[J]. Int J Clin OncolInt J Clin Oncol, 2011, 16(4): 408-415.
doi: 10.1007/s10147-011-0202-x |
| [11] |
Nagamachi S, Nishii R, Wakamatsu H, et al.
The usefulness of 18F-FDG PET/MRI fusion image in diagnosing pancreatic tumor: comparison with 18F-FDG PET/CT[J]. Ann Nucl MedAnn Nucl Med, 2013, 27(6): 554-563.
doi: 10.1007/s12149-013-0719-3 |
| [12] |
Chen BB, Tien YW, Chang MC, et al.
PET/MRI in pancreatic and periampullary cancer: correlating diffusion-weighted imaging, MR spectroscopy and glucose metabolic activity with clinical stage and prognosis[J]. Eur J Nucl Med Mol ImagingEur J Nucl Med Mol Imaging, 2016, 43(10): 1753-1764.
doi: 10.1007/s00259-016-3356-y |
| [13] |
Joo I, Lee JM, Lee DH, et al.
Preoperative assessment of pancreatic cancer with FDG PET/MR imaging versus FDG PET/CT plus contrast-enhanced multidetector CT: a prospective preliminary study[J]. RadiologyRadiology, 2017, 282(1): 149-159.
doi: 10.1148/radiol.2016152798 |
| [14] |
郝利国, 崔红升, 孟鑫, 等.
PET/MRI检查技术评估胰腺癌肿瘤可切除性的应用研究[J]. 临床放射学杂志临床放射学杂志, 2017, 36(8): 1129-1133.
doi: 10.13437/j.cnki.jcr.2017.08.020 Hao LG, Cui HS, Meng X, et al. The value of resectability of pancreatic cancer by PET/MR[J]. J Clin RadiolJ Clin Radiol, 2017, 36(8): 1129-1133. doi: 10.13437/j.cnki.jcr.2017.08.020 |
| [15] |
Furtado FS, Ferrone CR, Lee SI, et al.
Impact of PET/MRI in the treatment of pancreatic adenocarcinoma: a retrospective cohort study[J]. Mol Imaging BiolMol Imaging Biol, 2021, 23(3): 456-466.
doi: 10.1007/s11307-020-01569-7 |
| [16] |
Wang XY, Yang F, Jin C, et al.
Utility of PET/CT in diagnosis, staging, assessment of resectability and metabolic response of pancreatic cancer[J]. World J GastroenterolWorld J Gastroenterol, 2014, 20(42): 15580-15589.
doi: 10.3748/wjg.v20.i42.15580 |
| [17] |
Pakzad F, Groves AM, Ell PJ.
The role of positron emission tomography in the management of pancreatic cancer[J]. Semin Nucl MedSemin Nucl Med, 2006, 36(3): 248-256.
doi: 10.1053/j.semnuclmed.2006.03.005 |
| [18] |
Sahani DV, Bonaffini PA, Catalano OA, et al.
State-of-the-art PET/CT of the pancreas: current role and emerging indications[J]. RadiographicsRadiographics, 2012, 32(4): 1133-1158.
doi: 10.1148/rg.324115143 |
| [19] |
Izuishi K, Yamamoto Y, Sano T, et al.
Impact of 18-fluoro-deoxyglucose positron emission tomography on the management of pancreatic cancer[J]. J Gastrointest SurgJ Gastrointest Surg, 2010, 14(7): 1151-1158.
doi: 10.1007/s11605-010-1207-x |
| [20] |
Lytras D, Connor S, Bosonnet L, et al.
Positron emission tomography does not add to computed tomography for the diagnosis and staging of pancreatic cancer[J]. Dig SurgDig Surg, 2005, 22(1/2): 55-61.
doi: 10.1159/000085347 |
| [21] |
Farma JM, Santillan AA, Melis M, et al.
PET/CT fusion scan enhances CT staging in patients with pancreatic neoplasms[J]. Ann Surg OncolAnn Surg Oncol, 2008, 15(9): 2465-2471.
doi: 10.1245/s10434-008-9992-0 |
| [22] |
Gao J, Huang XY, Meng HP, et al. Performance of multiparametric functional imaging and texture analysis in predicting synchronous metastatic disease in pancreatic ductal adenocarcinoma patients by hybrid PET/MR: initial experience[J/OL]. Front Oncol, 2020, 10: 198[2021-03-27]. https://www.frontiersin.org/articles/10.3389/fonc.2020.00198/full. DOI: 10.3389/fonc.2020.00198. |
| [23] |
Katz MHG, Fleming JB, Bhosale P, et al.
Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators[J]. CancerCancer, 2012, 118(23): 5749-5756.
doi: 10.1002/cncr.27636 |
| [24] |
Panda A, Garg I, Truty MJ, et al.
Borderline resectable and locally advanced pancreatic cancer: FDG PET/MRI and CT tumor metrics for assessment of pathologic response to neoadjuvant therapy and prediction of survival[J]. AJR Am J RoentgenolAJR Am J Roentgenol, 2021, 217(3): 730-740.
doi: 10.2214/ajr.20.24567 |
| [25] |
Wang ZJ, Behr S, Consunji MV, et al.
Early response assessment in pancreatic ductal adenocarcinoma through integrated PET/MRI[J]. AJR Am J RoentgenolAJR Am J Roentgenol, 2018, 211(5): 1010-1019.
doi: 10.2214/ajr.18.19602 |
| [26] |
Chen BB, Tien YW, Chang MC, et al.
Multiparametric PET/MR imaging biomarkers are associated with overall survival in patients with pancreatic cancer[J]. Eur J Nucl Med Mol ImagingEur J Nucl Med Mol Imaging, 2018, 45(7): 1205-1217.
doi: 10.1007/s00259-018-3960-0 |
| [27] |
Dunet V, Halkic N, Sempoux C, et al.
Prediction of tumour grade and survival outcome using pre-treatment PET- and MRI-derived imaging features in patients with resectable pancreatic ductal adenocarcinoma[J]. Eur RadiolEur Radiol, 2021, 31(2): 992-1001.
doi: 10.1007/s00330-020-07191-z |
| [28] |
Sperti C, Pasquali C, Bissoli S, et al.
Tumor relapse after pancreatic cancer resection is detected earlier by 18-FDG PET than by CT[J]. J Gastrointest SurgJ Gastrointest Surg, 2010, 14(1): 131-140.
doi: 10.1007/s11605-009-1010-8 |
| [29] |
Ruf J, Hänninen EL, Oettle H, et al.
Detection of recurrent pancreatic cancer: comparison of FDG-PET with CT/MRI[J]. PancreatologyPancreatology, 2005, 5(2/3): 266-272.
doi: 10.1159/000085281 |